Regulated information
Waregem (Belgium)/Rotterdam (Netherlands)[1], 21 December 2015
Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies, Fagron received notification on 18 December 2015 that the shareholding of TIAA-CREF Asset Management LLC has fallen below the disclosure threshold of 3%.
Based on the denominator of 32,111,827 (total number of voting rights) and the latest received notifications, the major shareholders of Fagron are:
Number of shares % of effective voting rights Carmignac Gestion 2,463,267 7.67% Alychlo NV / Marc Coucke 1,709,601 5.32% Visium Asset Management LP 1,184,181 3.69%The original notification forms are available on the website investors.fagron.com.
In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.
For further information
Constantijn van Rietschoten
Chief Marketing Officer
Tel. +31 6 53 69 15 85
constantijn.van.rietschoten@fagron.com
Fagron profile
Fagron is a scientific pharmaceutical R&D company that is focused on optimizing and innovating customized pharmaceutical care. Fagron provides Fagron Specialty Pharma Services, Fagron Trademarks and Fagron Essentials to pharmacies, clinics and hospitals in 32 countries worldwide.
The Belgian company Fagron NV is located in Waregem and is listed on Euronext Brussels and Euronext Amsterdam. The operational activities of Fagron are driven by the Dutch company Fagron BV. The head office of Fagron BV is located in Rotterdam.
[1] This press release was sent out by Fagron NV and Fagron BV.
Please open the link below for the press release: